 Library
of Slides and Posters
Therapy
for Treatment-naive Patients
Therapy
for Treatment-experienced Patients
Experimental
Antiretrovirals
Protease
Inhibitors (PIs)
HIV-related
Complications
Drug Resistance
Pharmacokinetics
and Drug Interactions
Adverse
Events / Side Effects
 Therapy
for Treatment-naive Patients
Long-term
Efficacy and Safety of Fosamprenavir + Ritonavir (FPV/r) Versus Lopinavir/Ritonavir
(LPV/r) over 96 Weeks
F
Pulido and others. Copyright
GlaxoSmithKline. Used with permission, 2007.
The
Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with
Lamivudine and Efavirenz in HIV-1-Infected Patients: 3-Year Follow-up After Switching
Therapy
J Madruga and others.
Fosamprenavir
or Atazanavir Boosted with Ritonavir Given Once Daily with Tenofovir /Emtricitabine
in Antiretroviral Naïve HIV-Infected Patients: ALERT Study Virology Analysis Through
48 Weeks
K
Smith and others. Copyright
GlaxoSmithKline. Used with permission, 2007.
Therapy
for Treatment-experienced Patients
Efficacy
and Safety of Maraviroc in Antiretroviral-Experienced Patients Infected With CCR5-Tropic
HIV-1: 48-Week Results of MOTIVATE 1
J
Lalezari and others. (PowerPoint Format)
The
HIV Integrase Inhibitor Elvitegravir (EVG/r) Has Potent and Durable Antiretroviral
Activity in Treatment-Experienced Patients with Active Optimized Background Therapy
(OBT)
A Zolopa and others.
Experimental
Antiretrovirals
The
HIV Integrase Inhibitor Elvitegravir (EVG/r) Has Potent and Durable Antiretroviral
Activity in Treatment-Experienced Patients with Active Optimized Background Therapy
(OBT)
A Zolopa and others.
UK-453,061:
A NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR FOR THE TREATMENT OF DRUG-RESISTANT
HIV INFECTIONS
R Corbau and others.
Pharmacokinetics
of Coadministered Ritonavir-Boosted Elvitegravir Plus Maraviroc
S Ramanathan
and others.
GSK364735
is a Potent Inhibitor of HIV Integrase and Viral Replication
E Garvey
and others. Copyright
GlaxoSmithKline. Used with permission, 2007.
In
Vitro Antiviral Potency and Preclinical Pharmacokinetics of GSK364735 Predict
Clinical Efficacy in a Phase 2a Study
P
Golden and others. Copyright
GlaxoSmithKline. Used with permission, 2007.
A
Pharmacokinetic Interaction Between Lopinavir/r and Elvitegravir
A
Mathias and others.
Effect
of Atazanavir/r on the Steady-State Pharmacokinetics of Elvitegravir
A
Mathias and others.
Novel
2’-Fluoro Substituted Nucleotide HIV Reverse Transcriptase Inhibitor GS-9148 Exhibits
Low Potential for Mitochondrial Toxicity In Vitro
G
Laflamme and others.
Novel
Nucleotide Inhibitor GS-9148 Selects for a K70E Mutation in HIV-1 Reverse Transcriptase
and Low-Level Resistance In Vitro
G
Laflamme and others.
Resistance
Mechanisms of the K70E HIV-1 Reverse Transcriptase Mutant to GS-9148 and Other
NRTIs
K White
and others. Lack
of Clinically Relevant Drug Interactions Between Ritonavir-Boosted Elvitegravir
and TMC125
S Ramanathan and others.
Pharmacokinetics
of Coadministered Ritonavir-Boosted Elvitegravir Plus Maraviroc
S Ramanathan
and others.
Protease
Inhibitors (PIs)
Lopinavir
(LPV) Cerebrospinal Fluid (CSF) Trough Concentrations in HIV In HIV-Infected Adult
R
DiCenzo and others.
Long-term
Efficacy and Safety of Fosamprenavir + Ritonavir (FPV/r) Versus Lopinavir/Ritonavir
(LPV/r) over 96 Weeks
F
Pulido and others. Copyright
GlaxoSmithKline. Used with permission, 2007.
Effect
of Atazanavir/r on the Steady-State Pharmacokinetics of Elvitegravir
A
Mathias and others.
Drug
Resistance
Novel
Nucleotide Inhibitor GS-9148 Selects for a K70E Mutation in HIV-1 Reverse Transcriptase
and Low-Level Resistance In Vitro
G
Laflamme and others.
Resistance
Mechanisms of the K70E HIV-1 Reverse Transcriptase Mutant to GS-9148 and Other
NRTIs
K White
and others.
HIV-related
Complications
Incidence
and Economic Burden of Renal Disease in HIV
B Nordstrom and others.
Copyright GlaxoSmithKline. Used with permission, 2007.
Atovaquone
Suspension For Prophylaxis Against Pneumocystis Carinii Pneumonia In Allogeneic
Bone Marrow Or Stem Cell Transplantation Recipients Intolerant To Trimethoprim/Sulfamethoxazole
C
Ippoliti and others. Copyright
GlaxoSmithKline. Used with permission, 2007.
Pharmacokinetics
and Drug Interactions
Lack
of effect of efavirenz (EFV) 600 mg QD on the pharmacokinetics of tipranavir/ritonavir
500/200 mg BID (TPV/r) in healthy volunteers
C La Porte and others.
A
Pharmacokinetic Interaction Between Lopinavir/r and Elvitegravir
A
Mathias and others.
Effect
of Atazanavir/r on the Steady-State Pharmacokinetics of Elvitegravir
A
Mathias and others. Lack
of Clinically Relevant Drug Interactions Between Ritonavir-Boosted Elvitegravir
and TMC125
S Ramanathan and others. Pharmacokinetics
of Coadministered Ritonavir-Boosted Elvitegravir Plus Maraviroc
S Ramanathan
and others.
Adverse
Events / Side Effects
No
significant ECG effects are observed with therapeutic and supra-therapeutic doses
of tipranavir coadministered with ritonavir (TPV/r)
S
Huettner and others. The
Safety and Efficacy of Switching Stavudine to Tenofovir DF in Combination with
Lamivudine and Efavirenz in HIV-1-Infected Patients: 3-Year Follow-up After Switching
Therapy
J Madruga and others.
Clinical
Presentation of Hypersensitivity Reaction to Abacavir (ABC HSR) by HLA-B*5701
Status
C Martorell and others. Copyright GlaxoSmithKline. Used with
permission, 2007.
Novel
2’-Fluoro Substituted Nucleotide HIV Reverse Transcriptase Inhibitor GS-9148 Exhibits
Low Potential for Mitochondrial Toxicity In Vitro
G
Laflamme and others.
Miscellaneous
Comparison
of Markov and Discrete Event Simulation Models for HIV-Disease
K Simpson
and others. Efficacy
and Safety of Maraviroc in Antiretroviral-Experienced Patients Infected With CCR5-Tropic
HIV-1: 48-Week Results of MOTIVATE 1
J
Lalezari and others. (PowerPoint Format)
| 
